UAB Hematology Review 2021

 

UAB Hematology Review 2021
Avatar

Interferon for PV: Types, MOA, Effects in MPN, Pegylation of IFN, PEG vs. HU for High-Risk Disease, IFN Alfa-2 vs. HU, PEG-IFN Alfa-2b

By UAB Hematology Review 2021 FEATURING Pankit Vachhani
By UAB Hematology Review 2021 FEATURING Pankit Vachhani
352 views
March 18, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
Videos
09:00
UAB Hematology Review 2021

Sickle Cell Disease in Clinical Practice: Pathophysiology, Mortality…

Feat. J. Kanter
08:14
UAB Hematology Review 2021

New Therapies for Sickle Cell Disease in 2021: Crizanlizumab vs. Pla…

Feat. J. Kanter
13:34
UAB Hematology Review 2021

CLL Management in Times of COVID-19: Frontline Acalabrutinib or Ven …

Feat. M. Narkhede
20:13
UAB Hematology Review 2021

Advanced Stage cHL: Considering Frontline, Secondary, and Salvage Tr…

Feat. G. Goyal
37:07
UAB Hematology Review 2021

Hematopathology Pearls for Clinicians: Danger of “Preliminary Diagno…

Feat. D. Morlote
18:42
UAB Hematology Review 2021

2021 Updates on the Use of DOACs: Which GI/GU Patients Are Suitable …

Feat. J. May
21:42
UAB Hematology Review 2021

Hematologic Manifestations of COVID-19: Thrombosis Mechanisms and Ri…

Feat. R. Gangaraju
15:39
UAB Hematology Review 2021

2021 Updates on 2L CML and Beyond: TKIs (Imatinib, Dasatinib/Nilotin…

Feat. O. Jamy
24:58
UAB Hematology Review 2021

Interferon for PV: Types, MOA, Effects in MPN, Pegylation of IFN, PE…

Feat. P. Vachhani
24:01
UAB Hematology Review 2021

2021 UAB Updates on Relapsed DLBCL: Salvage Chemo+ASCT, Len+Rituxima…

Feat. A. Mehta
23:44
UAB Hematology Review 2021

Therapeutic Options for R/R MM: Single Agent vs. Doublets vs. Triple…

Feat. K. Godby
17:39
UAB Hematology Review 2021

Incorporating MoAbs in Frontline Treatment of MM: Assessing the Data…

Feat. S. Giri
14:06
UAB Hematology Review 2021

Frontline Daratumumab in MM: D-VTd vs. VTd, D-RVd vs. RVd in Transpl…

Feat. S. Bal
23:19
UAB Hematology Review 2021

Clinical Pearls: 2021 Review of Recently Approved Agents in Hematolo…

Feat. S. Worth
15:48
UAB Hematology Review 2021

UAB 2021 Updates on Frontline MDS: Can We Achieve AUC Decitabine at …

Feat. K. Bachiashvili